Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 1, 2017

View Archived Issues

GSK reflects on accomplishments of second quarter 2017

Takeda presents key events of first quarter of fiscal 2017

Exposure to MeNZB vaccine associated with reduced rates of gonorrhea diagnosis

First-in-human results for personalized RNA mutanome vaccine IVAC MUTANOME

FDA grants priority review to RBP-6000 NDA, clearance for buprenorphine assay

Kite Pharma submits MAA to EMA for axicabtagene ciloleucel

PellePharm announces topline phase II data for topical patidegib in Gorlin syndrome

Syndros, the first and only FDA-approved liquid dronabinol, becomes available by prescription

BLU-667, a RET inhibitor, shows promise for RET-driven thyroid cancer

Antigen Express and Merck & Co. agree to test AE-37 with Keytruda in triple-negative breast cancer

BLA submission for trastuzumab biosimilar ABP-980

Isogenica licenses antibody libraries to Takeda

FDA grants orphan drug designation to RA-101495 for PNH

Bayer discloses soluble guanylate cyclase activators

Aerie collaborates with DSM on technology to deliver compounds for retinal diseases

FDA accepts for review BLA for trastuzumab biosimilar CT-P6

Chemerin receptor antagonists presented by Shenzhen Institute of Advanced Technology

Celgene details pipeline developments of second quarter 2017

Recro submits NDA for intravenous meloxicam for postoperative pain

Phase III MAP US study of RHB-104 in Crohn's disease cleared to continue

New tau PET ligands [18F]AM-PBB3 and [18F]PM-PBB3 evaluated in humans

Bristol-Myers Squibb and Clovis sign clinical collaboration agreement to test Opdivo with Rubraca

FDA clears IND for phase I study of PTI-125 for Alzheimer's disease

Intercept reports results from trials of obeticholic acid in PSC and NASH

Emergent BioSolutions' development of auto-injector for nerve agent antidote gets financial support

Kitov announces NDA submission for KIT-302

Loxo to acquire Redx's BTK inhibitor program

FDA awards breakthrough therapy designation to acalabrutinib for mantle cell lymphoma

Lumosa initiates phase I trial of LT-3001 for acute ischemic stroke

Nerlynx launched in U.S.

Astellas seeks Japanese approval for fidaxomicin for infectious enteritis caused by C. difficile

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...